Faecalibacterium prausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial
Authors
David Tougeron (ORCID: https://orcid.org/0000-0002-8065-9635)
Faecalibacterium prausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial
David Tougeron, Ludovic Evesque, Christophe Louvet, Marius Bredon et al.
Citations
12 citations
Journal
Gastroenterology
Topics
Colorectal Cancer Treatments and Studies
Field-Weighted Citation Impact (FWCI)
3.39
article
Faecalibacterium prausnitzii Is Associated With Clinical Response to Immune Checkpoint Inhibitors in Patients With Advanced Gastric Adenocarcinoma: Results of Microbiota Analysis of PRODIGE 59-FFCD 1707-DURIGAST Trial
David Tougeron, Ludovic Evesque, Christophe Louvet, Marius Bredon, Harry Sokol, Karine le Malicot, Daniel Gonzalez
article en
12 citations
Abstract
No abstract available for this paper.
Publication Tag
GastroenterologyVol. 168(3)
Institutions
Inserm (FR), Institute Mutualiste Montsouris (FR), Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine (FR), Fédération Francophone de Cancérologie Digestive (FR), Centre Antoine Lacassagne (FR)